228 related articles for article (PubMed ID: 31875548)
1. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.
Parashar D; Geethadevi A; Aure MR; Mishra J; George J; Chen C; Mishra MK; Tahiri A; Zhao W; Nair B; Lu Y; Mangala LS; Rodriguez-Aguayo C; Lopez-Berestein G; Camara AKS; Liang M; Rader JS; Ramchandran R; You M; Sood AK; Kristensen VN; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cell Rep; 2019 Dec; 29(13):4389-4406.e10. PubMed ID: 31875548
[TBL] [Abstract][Full Text] [Related]
2. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.
Chaluvally-Raghavan P; Jeong KJ; Pradeep S; Silva AM; Yu S; Liu W; Moss T; Rodriguez-Aguayo C; Zhang D; Ram P; Liu J; Lu Y; Lopez-Berestein G; Calin GA; Sood AK; Mills GB
Cell Rep; 2016 May; 15(7):1493-1504. PubMed ID: 27160903
[TBL] [Abstract][Full Text] [Related]
3. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
5. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
7. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.
Menbari MN; Rahimi K; Ahmadi A; Mohammadi-Yeganeh S; Elyasi A; Darvishi N; Hosseini V; Abdi M
J Cell Physiol; 2020 Mar; 235(3):2631-2642. PubMed ID: 31508813
[TBL] [Abstract][Full Text] [Related]
8. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
[TBL] [Abstract][Full Text] [Related]
9. miR-23a-3p is a Key Regulator of IL-17C-Induced Tumor Angiogenesis in Colorectal Cancer.
Lee Y; Kim SJ; Choo J; Heo G; Yoo JW; Jung Y; Rhee SH; Im E
Cells; 2020 Jun; 9(6):. PubMed ID: 32492770
[TBL] [Abstract][Full Text] [Related]
10. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
12. miR-5590-3p-YY1 feedback loop promotes the proliferation and migration of triple-negative breast cancer cells.
Liang F; Fu X; Wang L
J Cell Biochem; 2019 Oct; 120(10):18415-18424. PubMed ID: 31190375
[TBL] [Abstract][Full Text] [Related]
13. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson BL; Junk DJ; Cipriano R; Jackson MW
Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
[TBL] [Abstract][Full Text] [Related]
15. miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2.
Zhao M; Zhang M; Tao Z; Cao J; Wang L; Hu X
Technol Cancer Res Treat; 2020; 19():1533033820905824. PubMed ID: 32174262
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
18. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
19. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling.
Lapeire L; Hendrix A; Lambein K; Van Bockstal M; Braems G; Van Den Broecke R; Limame R; Mestdagh P; Vandesompele J; Vanhove C; Maynard D; Lehuédé C; Muller C; Valet P; Gespach CP; Bracke M; Cocquyt V; Denys H; De Wever O
Cancer Res; 2014 Dec; 74(23):6806-19. PubMed ID: 25252914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
